Supernus Pharma announces issuance of two patents covering Trokendi XR

Supernus Pharmaceuticals announced the issuance of two patents -- 8,298,576 and 8,298,580 -- by the US Patent and Trademark Office, or USPTO, covering Trokendi XR, its novel once-daily extended-release topiramate product. Both patents were issued by the USPTO on Oct. 30. Each of our epilepsy products, Trokendi XR and Oxtellar XR, is now covered by two issued US patents

View Comments (0)